Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301–2307.

    Article  CAS  PubMed  Google Scholar 

  2. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RA, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220–16225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol 2007; 139: 194–205.

    Article  CAS  PubMed  Google Scholar 

  4. Minderman H, Zhou Y, O'Loughlin KL, Baer MR . Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007; 60: 245–255.

    Article  CAS  PubMed  Google Scholar 

  5. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371–3376.

    Article  CAS  PubMed  Google Scholar 

  6. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kurdik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065.

    Article  CAS  PubMed  Google Scholar 

  7. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060–1066.

    Article  CAS  PubMed  Google Scholar 

  8. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781–2790.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133–142.

    Article  CAS  PubMed  Google Scholar 

  10. Emanuele S, Lauricella M, Carlisi D, Vassallo B, D’Anneo A, Di Fazio P et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007; 12: 1327–1338.

    Article  CAS  PubMed  Google Scholar 

  11. Holkova B, Perkins EB, Sokol L, Richards KL, Parekh S, Elstrom R et al. A Phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large b-cell lymphoma. Blood 2011; 118, ASH abstract 779.

    Google Scholar 

  12. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319–324.

    Article  CAS  PubMed  Google Scholar 

  13. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer group study. Neuro Oncol 2012; 14: 215–221.

    Article  CAS  PubMed  Google Scholar 

  14. Dimopoulos MA, Jagannath S, Yoon S, Siegel D, Lonial S . Vantage 088: vorinostat in combination with bortezomib in patients with refractory/relapsed multiple myeloma: results of a global, randomized phase 3 trial. Blood 2011; 118, ASH abstract 811.

    Article  Google Scholar 

  15. Siegel D, Dimonopoulos, Yoon S, Laubach J, Kaufman J . Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood 2011; 118, ASH abstract 480.

    Article  Google Scholar 

Download references

Acknowledgements

Funding support for the entire clinical trial was provided jointly by Millenium and Merck.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E D Warlick.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warlick, E., Cao, Q. & Miller, J. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity. Leukemia 27, 1789–1791 (2013). https://doi.org/10.1038/leu.2013.61

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.61

This article is cited by

Search

Quick links